

Corp. Off.: 502, Kanakia Atrium - 2, Next to Courtyard Marriott Hotel, Andheri Kurla Road, Andheri (East),

Mumbai - 400 093 (India)

Ph.: + 91 22 61933100 Fax: +91 22 61933114

27<sup>th</sup> May, 2016

#### **BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street Mumbai-400001

Scrip Code: 533543

### National Stock Exchange of India Ltd.

Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai-400051

Symbol: BROOKS

Sub: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today 27<sup>th</sup> May, 2016 has, inter alia, approved the Audited Financial Results of the Company for Quarter & Year ended 31<sup>st</sup> March, 2016.

Enclosed please find herewith the following

- 1. Audited standalone financial results of the Company for the financial year ended 31<sup>st</sup> March, 2016 and the financial results of the Company in respect of the fourth quarter of FY 2015-16,
- 2. The Standalone Statement of Assets and Liabilities.
- 3. The Auditors Report,
- 4. and the Form A,

The aforesaid result and report are attached for your record.

Thanking You,

Yours faithfully

For BROOKS LABORATORIES LIMITED

(Jyoti Sancheti)

Company Secretary cum Compliance Officer

Encl.: As above

# BROOKS LABORATORIES LIMITED Regd Office: Village Kishanpura, Nalagarh Road, Baddi, Dist. Solan H.P.-174101 CIN NO: L24232HP2002PLC000267

Tel No: +91 1795 654001/02/03, Fax No: +91 1795 236939, E-mail: investors@brookslabs.net, Website: www.brookslabs.net Audited Financial Results for the Quarter/ Year Ended March 31, 2016

PART I					(Rs. in Lacs)
ARTI		uarter Ended		Year Ended	Year ended
Particulars		31.12.2015	31.03.2015	31.03.2016	31.03.2015
i ai ticulai 3	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1 Income from operations					
(a) Net sales (Net of excise duty)	2,069.33	2,086.73	2,351.43	8,000.94	8,521.33
Total income from operations (net)	2,069.33	2,086.73	2,351.43	8,000.94	8,521.33
*					
2 Expenses		1 000 10	1.660.66	5,259.55	6.041.14
(a) Cost of materials consumed	1,248.42	1,390.12	1,669.66	5,259.55	0,041.14
(b) Changes in inventories of finished goods & we	ork-in-		(05.04)	24.60	23.61
progress	29.77	(16.93)	(25.24)	34.68	474.67
(c) Employee benefits expense	204.23	185.38	120.19	707.84	110.36
(d) Depreciation and amortisation expense	29.15	30.28	26.44	116.00	Contraction Contraction (
(e) Other Expenses	212.01	224.91	383.05	890.53	1,295.80
Total expenses	1,723.58	1,813.76	2,174.10	7,008.60	7,945.58
*					
3 Profit / (Loss) from operations before other in	ncome,		485.00	992.34	575,75
finance costs and exceptional items (1-2)	345.75	272.97	177.33		225.17
4. Other income	21.76	53.65	37.18	156.10	223.17
5 Profit / (Loss) from ordinary activities before	finance				000.02
costs and exceptional items (3 + 4)	367.51	326.62	214.51	1,148.44	800.92
6 Finance costs	10.16	35.69	11.16	79.44	44.34
7 Profit / (Loss) from ordinary activities after f	inance				
costs but before exceptional items (5 - 6)	357.35	290.93	203.35	1,069.00	756.58
8 Exceptional items / Prior period items	12.88	-	68.29	12.88	278.47
9 Profit / (Loss) from ordinary activities before	tax (7-				
	370.23	290.93	271.64	. 1,081.88	1,035.05
8)	(92.12	and the second second second second	37.39	18.55	88.32
10 Tax expense (Refer Note 2)		,			
11 Net Profit / (Loss) from ordinary activities af	462.35	279.46	234.25	1,063.33	946.73
10)	402.55	2,5110			2
12 Extraordinary items	462.35	279.46	234.25	1,063.33	946.73
13 Net Profit / (Loss) for the period (11 + 12)	1,618.64		1,618.64		
14 Paid-up equity share capital	1,010.04	1,010.04	1,010.01		
(Face Value Rs.10/- per share)					
15 Reserve excluding Revaluation Reserves as per	palance .		1 -	10,586.37	9,523.04
cheet of previous accounting year		1		10,000.07	
16 i Farnings per share (before extraordinary ite	ms)		1		1
(of Rs.10/- each) (not annualised):	1		1.45	6.57	5.85
(a) Basic -in Rs.	2.86	1			
(b) Diluted- in Rs.	2.86	5 1.73	1.45	0.57	3.55
Law (often extraordinary item	16)				
16.ii Earnings per share (after extraordinary iten	, cou	180	1		1
(of Rs.10/- each) (not annualised):	2.8	6 1.73	1.45		
(a) Basic -in Rs.	2.8		1	6.57	5.85
(b) Diluted- in Rs.	2.0	2172			

#### Notes:

- 1 The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 27, 2016.
- 2 Tax expense includes Current Tax, Mat Credit Entitlement, Defered Tax & Taxes for earlier years. Tax expense for the quarter includes reversal of excess provision of tax for earlier years of Rs 61.92 lacs & Mat credit entitlment of Rs. 60.38 lacs for earlier years. For the year includes Rs 8.55 lacs (net of excess provision of Rs 61.92 lacs & short provision of Rs 70.47 lacs) for taxes of earlier years & Mat credit entitlement of Rs. 60.38 lacs.
- 3 The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment as per Accounting Standard (AS-17).
- 4 The figure for the quarter ended March 31, 2016 are the balancing figure between audited figures in respect of full financial year and published figure for the nine months ended on December 31, 2015.
- 5 Figures of the previous period / year have been reclassified/ regrouped wherever necessary.

Date: May 27, 2016

Place: Mumbai

For and on behalf of the Board

Rajesh Mahajan DIN No.: 02000634 Managing Director

502, Kanakia Atrium-2, Andheri (E) Mumbai - 93,

### **Brooks Laboratories Limited**

Standalone Statement of Assets and Liabilities as on March 31, 2016
(Rs. in Lacs)

		(Rs. in Lacs)
	Year ended	Year ended
Particulars	31.03.2016	31.03.2015
A SAN SAN SAN SAN SAN SAN SAN SAN SAN SA	(Audited)	(Audited)
A   EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	1,618.64	1,618.64
(b) Reserves and surplus	10,586.37	9,523.04
Sub-total - Shareholders' funds	12,205.01	11,141.68
2 Non-current liabilities		
(a) Long-term borrowings	34.24	
(b) Deferred tax liabilities (net)	146.10	132.90
(c) Long-term provisions	76.18	66.17
(c) hong term provisions		
Sub-total - Non-current liabilities	256.52	199.07
3 Current liabilities		
(a) Short-term borrowings	528.36	51.25
(b) Trade payables	1,592.28	1,904.24
(c) Other current liabilities	540.64	180.26
(d) Short-term provisions	130.87	78.18
Sub-total - Current liabilities	2,792.15	2,213.93
TOTAL - EQUITY AND LIABILITIES	15,253.68	13,554.68
B ASSETS		
1 Non-current assets		6.054.76
(a) Fixed assets	10,342.46	6,854.76
(b) Non-current investments	2.00	1
(c) Long-term loans and advances	1,656.05	1,219.66
Sub-total - Non-current asset	s 12,000.51	8,076.42
2 Current assets		753.39
(a) Inventories	668.89	1
(b) Trade receivables	1,891.44	
(c) Cash and cash equivalents	222.58	
(d) Short-term loans and advances	448.49	
(a) Other current assets	21.77	
Sub-total - Current asset	3,253.17	The state of the s
TOTAL - ASSET	S 15,253.68	13,334.00

For Brooks Laboratories Ltd.

Managing Director
DIN No. 02000634



Auditor's Report on Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

## To The Board of Directors of Brooks Laboratories Limited

1. We have audited the accompanying statement of Financial Results of Brooks Laboratories Limited ("the Company") for the quarter ended March 31, 2016 and year to date results for the period from April 1, 2015 to March 31, 2016 attached herewith ("the Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has prepared on the basis of the related financial statements which are in accordance with the Accounting Standards prescribed under the section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement.

We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered accountants of India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether statement is free from material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed in the statement. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the significant accounting estimates made by the Management, as well as evaluating the overall presentation of the statement. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

- 2. In our opinion and to the best of our information and according to explanation given to us ,the statement;
  - (i) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015; and
  - (ii) Gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally accepted in India of the net profit and other financial Information of the Company for the year ended 31st March 2016.

4A, Kaledonia-HDIL, 2<sup>nd</sup> Floor, Sahar Road, Near Andheri Station, Andheri (East), Mumbai - 400 069. India Tel.: +91 22 6625 6363 Fax: +91 22 6625 6364 E-mail: info@sgco.co.in www.sgco.co.in



### SGCO&Co. Chartered Accountants

3. The statement includes the results for the Quarter ended 31st March 2016 being the balancing figure between the audited figures in respect of the full financial year and the published year to dated figures up to the third quarter of the current financial year which were subject to limited review by us.

FRN - 112081W MUMBAI

For S G C O & Co. Chartered Accountants Firm's Reg. No. 112081W

Suresh Murarka

Partner Mem. No. 44739

Place : Mumbai Date: 27th May, 2016



#### A WHO GAR & ISO : 9001-2009 Certified Company

Corp. Off.: 502, Kanakia Atrium - 2, Next to Courtyard Marriett Hotel, Andheri Kurla Road, Andheri (East), Mumbai - 400 093 (India) Ph.: + 91 22 61933100 Fax::+91 22 61933114

# Form A. [Pursuant to Regulation 33 of SEBI (LODR) Regulations,2015]

1.	Name of the Company	Brooks Laboratories Limited
2.	Annual financial statements for the year ended	31st March 2016
3,	Type of Audit observation	Un Modified
4.	Frequency of observation.	Not Applicable
5,	Signed by-	
	Director Name (KMP)	Rajesh Mahajan Managing Director
	Chief Financial Officer (KMP)	Anii Kumar Pillai
	Auditor of the company	Fors G.C.O. & Co. Charlered Accountants Firm Reg. No. 110081W  Suresh Murarka Partner Mem. No. 44739
	Audit Committee Chairman	Rajnish Kumar Bedi

Date:May 27, 2016 Place: Mumbai